Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.48 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.46 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30886748 | 1.00 | LPAR3 (0.58) | LPAR3LPAR1LPAR2ENPP2LPAR6 | |
| SCHEMBL30293860 | 1.00 | LPAR3 (0.58) | LPAR3LPAR1LPAR2ENPP2LPAR6 | |
| SCHEMBL29612842 | 0.92 | LPAR3 (0.66) | LPAR3LPAR1LPAR2ENPP2LPAR6 | |
| SCHEMBL29922353 | 0.92 | LPAR3 (0.66) | LPAR3LPAR1LPAR2ENPP2LPAR6 | |
| SCHEMBL31182056 | 0.89 | LPAR1 (0.64) | LPAR3LPAR1LPAR2ENPP2LPAR6 | |
| SCHEMBL30184437 | 0.86 | LPAR3 (0.47) | LPAR3LPAR1LPAR2ENPP2LPAR6 | |
| SCHEMBL9066004 | 0.81 | DNM1 (0.47) | — | |
| SCHEMBL31456017 | 0.79 | SELP (0.48) | LPAR3LPAR1LPAR2ENPP2LPAR6 | |
| SCHEMBL31530631 | 0.79 | SELP (0.48) | LPAR3LPAR1LPAR2ENPP2LPAR6 | |
| SCHEMBL31521692 | 0.79 | SELP (0.48) | LPAR3LPAR1LPAR2ENPP2LPAR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12239708-B2 | Dry powder inhalation formulation and its use for the therapeutic treatment of lungs | Université Libre de Bruxelles (BE) | 2025-03-04 | — | — | US | claimed |
| EP-3902520-B1 | KIT FOR INHALED CHEMOTHERAPY, AND TREATMENT OF LUNG CANCER WITH SAID KIT | UNIV BRUXELLES (BE) | 2025-02-05 | — | — | EP | claimed |
| US-20240118198-A1 | NEAR INFRARED-II REGION FLUORESCENT RARE EARTH NANOPROBE TEST STRIP AND ITS PREPARATION METHOD | Shandong Laboratory of Yantai Drug Discovery (CN) | 2024-04-11 | — | — | US | claimed |
| CN-117241780-A | Biological delivery system | 帕帝塞拉公司 | 2023-12-15 | — | — | CN | claimed |
| US-11833254-B2 | Discoidal nano universal platform for efficient delivery of PNAs | UNIVERSITY OF CONNECTICUT (US) | 2023-12-05 | — | — | US | claimed |
| US-20230302154-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-09-28 | — | — | US | claimed |
| CN-113288871-B | Pharmaceutical composition liposome formulations for modulation of epigenetic and immune checkpoints | 华中科技大学 | 2022-09-16 | — | — | CN | claimed |
| WO-2022040435-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | WO | claimed |
| EP-4737439-A1 | IONIZABLE LIPID AND USE THEREOF | Axter Therapeutics (Beijing) Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4729509-A1 | IONIZABLE LIPID FOR MUSCLE-SPECIFIC DELIVERY | Beijing Jitai Life Sciences Ltd (CN) | 2026-04-22 | — | — | EP | disclosed |
| EP-4719497-A1 | METHODS FOR TREATING SSTR POSITIVE CANCER | Rayzebio, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2026007226-A1 | NANOPARTICLE LOADED WITH ORAL PROTEIN DRUG FOR TREATMENT OF DIABETES AND CARRIER | 中国科学院过程工程研究所 | 2026-01-08 | — | — | WO | disclosed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| CN-115461354-B | Tandem repeat cancer targeting peptides for molecular conjugation or engineering and their use in cancer therapeutic diagnostics | 长庚医疗财团法人林口长庚纪念医院 | 2025-05-09 | — | — | CN | disclosed |
| WO-2022227080-A1 | PORE ARRAY LAYER STRUCTURE, CHIP DEVICE, NANOPORE SEQUENCING DEVICE, AND FILM FORMING METHOD AND USE THEREOF | 成都齐碳科技有限公司 | 2022-11-03 | — | — | WO | disclosed |
| CN-113288871-B | Pharmaceutical composition liposome formulations for modulation of epigenetic and immune checkpoints | 华中科技大学 | 2022-09-16 | — | — | CN | disclosed |
| US-20220288285-A1 | CATIONIC NANODRUG, PREPARATION METHOD THEREFOR, AND DRUG-LOADED IMPLANTABLE MEDICAL DEVICE | SHANGHAI MICROPORT MEDICAL (GROUP) CO., LTD. (CN) | 2022-09-15 | — | — | US | disclosed |
| EP-4026536-A1 | CATIONIC NANODRUG, PREPARATION METHOD THEREFOR, AND DRUG-LOADED IMPLANTABLE MEDICAL DEVICE | Shanghai MicroPort Medical (Group) Co., Ltd. (CN) | 2022-07-13 | — | — | EP | disclosed |
| WO-2022040435-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | WO | disclosed |
| CN-113993545-A | Pharmaceutical composition for treating tumor | 卫材R&D管理有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833254-B2 | Discoidal nano universal platform for efficient delivery of PNAs | PHOSPHO1, PNLIP, DNTT | LPAR3 154/4885LPAR1 121/4885LPAR2 124/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | LPAR3 1326/4885LPAR1 919/4885LPAR2 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.